Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells

Published:2012-03-11 Issue:10 Volume:61 Page:1735-1743
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Zhou Yan,He Jing,Gou Lan-tu,Mu Bo,Liao Wei-chan,Ma Cong,Tang Ping,Zhou Shi-jie,Zhou Yong-jun,Yang Jin-liang

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-011-1194-0.pdf

Reference41 articles.

1. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK (2009) Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15(8):2695–2702. doi: 1078-0432.CCR-08-2966

2. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48–52. doi: S0090-8258(09)00139-5

3. Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC (2009) The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116(3):372–380. doi: 10.1111/j.1471-0528.2008.02033.x

4. Chiodoni C, Iezzi M, Guiducci C, Sangaletti S, Alessandrini I, Ratti C, Tiboni F, Musiani P, Granger DN, Colombo MP (2006) Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203(11):2441–2450. doi: jem.20060844

5. Maisch T, Kropff B, Sinzger C, Mach M (2002) Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J Virol 76(24):12803–12812

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities;Drug Discovery Today;2023-08

2. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas;World Neurosurgery;2019-10

3. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer;Current Gene Therapy;2019-05-28

4. Prognostic values of GMPS, PR, CD40, and p21 in ovarian cancer;PeerJ;2019-01-25

5. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy;Cancer Immunology, Immunotherapy;2018-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3